CRMD

ANALYST NOTE: CRMD (CorMedix Inc.) Date: 2026-06-13 Analyst: StoryStocks-Native Equity Research

1. Structural Readiness

Setup State: Forming Current Price: $8.67 Coil Classification: FORMING

• Conservative Entry: Not yet actionable (requires confirmed breakout above $17.43).
• Aggressive Entry: $7.53 (Pre-breakout / forming entry).
• Extension: None (Price is well below the breakout target).
• ATR Context: Current ATR is 3.6% (productive). This volatility is within the historical "sweet spot" (4–6%) for structural quality, though slightly below the high-volatility threshold often seen in confirmed breakouts.

2. Thesis Layer

Primary Secular Theme: Biotech & GLP-1 → Rare & Orphan (Tier: Second Order, Confidence: Low) Thesis Weighting: CorMedix is a direct beneficiary of the "Rare & Orphan" sub-theme within the broader Biotech sector, specifically through its commercialization of DefenCath for catheter-related bloodstream infections (CRBSI) in dialysis patients. While the "Biotech & GLP-1" label is broad, the specific exposure here is to the "Rare & Orphan" niche of anti-infectives. Context: The company is not a primary driver of the GLP-1 narrative but is a secondary-order beneficiary of the broader biotech commercialization environment. The conviction in this theme is currently low relative to the company's specific execution risks and reimbursement headwinds, though the commercial traction of DefenCath provides a tangible, albeit niche, secular tailwind.

3. The Business

Company Overview: CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for infectious and inflammatory conditions. Its primary business model relies on the commercialization of its lead product, DefenCath (Neutrolin), a novel anti-infective solution for preventing catheter-related bloodstream infections. Business Model & Industry: The company operates in the Healthcare industry, specifically the medical devices/pharmaceuticals intersection for dialysis care. Supporting Evidence (as of 2026-06-13):

• Revenue Growth: For the three months ended March 31, 2026, Product Sales reached $121.9 million, a 212% increase ($82.8 million) year-over-year compared to $39.1 million in Q1 2025. This growth is attributed to sustained DefenCath demand and the addition of the Melinta portfolio revenue.
• Revenue Composition: Q1 2026 revenue included $97.5 million from DefenCath and $29.9 million from the Melinta portfolio.
• Market Penetration: Management states that contracted customers represent roughly 60% of the outpatient dialysis centers in the U.S. in terms of the total addressable patient market.
• Guidance: Management has raised full-year 2026 financial guidance. Net revenue is now expected to be $325 million to $345 million (up from $300–$320 million). Adjusted EBITDA is raised to $115 million to $135 million (up from $100–$125 million). DefenCath revenue specifically is guided to $175 million to $195 million (up from $150–$170 million).
• Commercial Expansion: The company expects to incur incremental spend in the back half of 2026, adding 15 to 20 incremental headcount across commercial and medical functions.
• Pipeline: Positive Phase III topline results were announced for REZZAYO (rezafungin) for prophylaxis in hematopoietic stem cell transplant patients, with commercialization targeted for 2027 if approved.

4. Archetype and Conviction

Archetype: Quality Compounder Rationale: The company fits the "Quality Compounder" archetype due to its demonstrated ability to scale revenue rapidly (212% YoY growth) and expand margins (raised EBITDA guidance) while maintaining a clear path to profitability. The business model has transitioned from pure R&D to a commercial operator with significant recurring revenue potential in the dialysis sector. Valuation & Financial Spine:

Conviction Stack:

• Forward consensus EPS for FY1 is $0.50667, with FY2 estimated at $0.13.
• The company estimates sufficient cash, cash equivalents, and short-term investments to fund operations for at least twelve months from the issuance of the Q1 2026 financial statements.
• Thesis Strength: Moderate. The "Rare & Orphan" theme is niche, but the commercial execution is strong.
• Evidence Quality: High. Multiple primary sources (earnings transcripts, SEC filings) confirm revenue surges and raised guidance.
• Rerating Potential: High, contingent on the successful navigation of the TDAPA reimbursement cliff in H2 2026 and the subsequent 2027 pricing recovery.

5. Invalidations, Strengths, and Gaps

What Would Invalidate the Case:

• Fundamental: A significant miss on the raised H2 2026 guidance, particularly if the "significant decline" in reimbursement (as warned by CMS methodology) is worse than anticipated, or if the Melinta portfolio revenue fails to sustain.
• Regulatory: Failure to submit the sNDA for DefenCath in the second half of 2026 or a negative FDA response to the pre-NDA meeting.

What Would Strengthen the Case:

• Structural: A confirmed breakout above $17.43 with volume expansion.
• Fundamental: Confirmation that the "post-TDAPA Add-On Adjustment" in 2027 yields the "meaningful increase" in payment rates management expects, offsetting the H2 2026 decline.
• Pipeline: Positive data readout or FDA approval for REZZAYO in the second indication, accelerating the 2027 commercialization timeline.

Gaps in Evidence:

• Reimbursement Specifics: While management expects a decline in H2 2026 and an increase in 2027, the exact magnitude of the "significant decline" and the specific "meaningful increase" are based on CMS methodology estimates, not finalized rates.
• Melinta Sustainability: The $29.9 million contribution from Melinta is noted, but the long-term sustainability of this revenue stream post-Q1 2026 is not fully detailed in the provided evidence beyond "typical first quarter purchasing patterns."
• 2027 Pricing: The expectation of higher net selling prices in 2027 is a management expectation based on the TDAPA add-on calculation, but the actual CMS determination has not yet occurred.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key risks: Significant decline in DefenCath net pricing in H2 2026 due to TDAPA reimbursement methodology; Execution risk on 2027 pricing recovery; Potential failure to sustain Melinta portfolio revenue. Sizing hint: Position size should reflect the "forming" nature of the setup and the binary nature of the reimbursement cliff; smaller than a confirmed breakout position. Expected path: Management expects a pricing dip in H2 2026 followed by a recovery in 2027; the stock likely consolidates near current levels or tests the breakout level of $17.43 if the 2027 outlook is reinforced by market data. Expected horizon: 6 to 12 months to see the impact of the H2 2026 pricing dynamics and the 2027 outlook.